Cogent Biosciences (COGT) Change in Accured Expenses (2017 - 2026)

Cogent Biosciences (COGT) has reported Change in Accured Expenses for 10 consecutive years, with -$10.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 17.81% year-over-year to -$10.2 million; the TTM figure through Mar 2026 stood at $9.1 million (down 34.77% YoY), while the FY2025 annual figure was $10.7 million, down 33.03% from the prior year.
• Change in Accured Expenses declined to -$10.2 million in Q1 2026 per COGT's latest filing, from $9.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.1 million in Q2 2024 and bottomed at -$10.2 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 1384.92% — and 2024, when it soared 446.08%.
• Cogent Biosciences' Change in Accured Expenses stood at $3.8 million in 2022, then plunged by 30.93% to $2.6 million in 2023, then jumped by 115.41% to $5.7 million in 2024, then surged by 60.75% to $9.1 million in 2025, then plunged by 212.09% to -$10.2 million in 2026.
• Business Quant data shows COGT's Change in Accured Expenses at -$10.2 million in Q1 2026, $9.1 million in Q4 2025, and $4.6 million in Q3 2025.